HER2-positive tumours, 95.4% of which were treated with HER2-targeting agents preoperatively, had the highest probability of achieving pCR regardless of ER status: 45.6% in the entire population and 60.7% and 35.2% in the ER-negative and ER-positive subgroups, respectively. Here, ERBB2 is linked to neoplasm.